MATERIAL AND METHODS
Acute hypotensive action of nifedipine and of the combination of nifedipine and propranolol:
Five male patients with essential hypertension were selected for the trials. All medications, including anti-hypertensive drugs, were discontinued for 4 weeks. After 2 hours' bed rest in a metabolic room of the hospital, in the supine position, blood pressure and heart rate were measured. Patients received nifedipine 10mg sublingually, and blood pressure and heart rate checks were repeated every 30min for 2 hours. Plasma renin activity was measured before and after the test. One week later, the combination of nifedipine (10mg) and propranolol (0.2mg/Kg body weight, intravenously) was administered to the same patients and blood pressure, heart rate, and plasma renin activity were measured as in the first test. Clinical data of the patients are listed in Table I. 2. Long-term therapy with combination of nifedipine and propranolol, and the combination of nifedipine and propranolol, and the combination of nifedipine, propranolol, and diuretic:
Twenty-five patients with essential hypertension were admitted to this trial. They were subdivided into 3 groups: 
RESULTS

Acute hypotensive action:
Nifedipine significantly lowered blood pressure with the increase in heart rate and plasma renin activity. The combined administration of nifedipine and propranolol lowered blood pressure with the significant decrease of plasma renin activity, and the significant fall in heart rate. The combined administration markedly decreased the rate-pressure product ( Fig. 1 
Long-term therapy:
Group I: The combined administration of nifedipine and propranolol and of nifedipine, propranolol, and diuretic markedly decreased blood pressure, heart rate, and rate-pressure product.
Abnormal electrocardiographic findings, increased cardiothoracic ratios and hypertensive retinopathies were significantly improved.
Blood urea nitrogen and plasma renin activity decreased slightly (Tables III and IV) . Patients with acute myocardial infarction could be well managed, anginal attacks were less frequent or disappeared completely after the one-week treatment.
Group II: The combination of nifedipine and propranolol and of nifedipine, propranolol, and diuretic significantly lowered blood pressure, heart rate, and rate-pressure product.
Abnormal electrocardiographic findings, retinopathies, and plasma renin activity were significantly improved.
Cardiothoracic ratio and blood urea nitrogen slightly decreased (Table IV) .
Group III:
The combination of nifedipine and propranolol significantly reduced blood pressure, heart rate, and rate-pressure product. High voltage of electrocardiograms and plasma renin activity decreased significantly (Table IV) tion of propranolol12),13) and methyldopa.17) Drug related palpitations are prevented by the additional medication with propranolol.12),13) A pronounced hypotensive effect was observed after the administration of nifedipine alonel2)-16) and the return of blood pressure to pre-treatment levels could be delayed by the combination of nifedipine and propranolol12),13) or methyldopa.17) Nifedipine with propranolol13) or methyldopa17) improved the left ventricular function. The filling pressure was diminished,17) but stroke volume and cardiac output increased13),17) after nifedipine. The reductions of afterload13),17) and the impedance of the left ventricular ejection17) by the reduction of total peripheral resistance13),17) may have improved the left ventricular function.
In our present trials, we confirmed that nifedipine alone lowered blood pressure with a slight increase in heart rate and plasma renin activity.12) The combination of nifedipine and propranolol, however, reduced blood pressure with the decrease in heart rate and plasma renin activity.12) Palpitation and headache sometimes caused by nifedipine, were almost not observed when the two drugs were given together.
The effective management of the hypertensive patient with coronary heart disease is aimed at the reduction of pathologically elevated blood pressure and rate-pressure product to near normal levels, in order to prevent severe complications, such as hypertensive heart failure, encephalopathy, and renal failure. With the combination therapy, a long-term satisfactory management of our patients could be achieved. The findings that the combination therapy Jpn. Heart J. J uly 1981 
